Significant Fibrosis Is Not Rare in Chinese Chronic Hepatitis B Patients with Persistent Normal ALT

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Liao, Baolin ^a,b   Wang, Zhanhui ^a   Lin, Siwei ^c   Xu, Ying ^a   Yi, Junqing ^b   Xu, Min ^b   Huang, Zuxiong ^a   Zhou, Ying ^b   Zhang, Fuchun ^b   Hou, Jinlin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c Yuexiu District Traditional Chinese Medicine Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; ASPARTATE AMINOTRANSFERASES; CHINA; COHORT STUDIES; FEMALE; FIBROSIS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; YOUNG ADULT;

EID: 84886441539     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078672     Document Type: Article

References (39)

1. Dienstag JL, (2008) Hepatitis B virus infection. N Engl J Med 359: 1486-1500. doi:10.1056/NEJMra0801644. PubMed: 18832247.
2. Yuen MF, Hou JL, Chutaputti A, (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24: 346-353. doi:10.1111/j.1440-1746.2009.05784.x. PubMed: 19220670.
3. Lavanchy D, (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107. doi:10.1046/j.1365-2893.2003.00487.x. PubMed: 14996343.
4. Mani H, Kleiner DE, (2009) Liver biopsy findings in chronic hepatitis B. Hepatology 49: S61-S71. doi:10.1002/hep.22930. PubMed: 19399798.
5. Fung J, Lai CL, Seto WK, Yuen MF, (2011) The use of transient elastography in the management of chronic hepatitis B. Hepatol Int 5: 868-875. doi:10.1007/s12072-011-9288-5. PubMed: 21695588.
6. ter Borg F, ten KF, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, et al. (2000) A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. J Clin Pathol 53: 541-548. doi:10.1136/jcp.53.7.541. PubMed: 10961179.
7. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618. doi:10.1111/j.1572-0241.2002.06038.x. PubMed: 12385448.
8. Liaw Y, Kao J, Piratvisuth T, Chan H, Chien R, et al. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6: 531-561. doi:10.1007/s12072-012-9365-4.
9. Lok AS, McMahon BJ, (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661-662. doi:10.1002/hep.23190. PubMed: 19714720.
10. European, Association for The Study of The Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185. PubMed: 22436845.
11. Seto WK, Lai CL, Ip PP, Fung J, Wong DK, et al. (2012) A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLOS ONE 7: e32622. doi:10.1371/journal.pone.0032622. PubMed: 22389715.
12. Park JY, Park YN, Kim DY, Paik YH, Lee KS, et al. (2008) High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat 15: 615-621. doi:10.1111/j.1365-2893.2008.00989.x. PubMed: 18573162.
13. Chan HL, Tsang SW, Liew CT, Tse CH, Wong ML, et al. (2002) Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 97: 406-412. doi:10.1111/j.1572-0241.2002.05478.x. PubMed: 11866280.
14. Shao J, Wei L, Wang H, Sun Y, Zhang LF, et al. (2007) Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol 13: 2104-2107. PubMed: 17465456.
15. Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, et al. (2008) The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol 49: 884-891. doi:10.1016/j.jhep.2008.06.009. PubMed: 18674840.
16. Bedossa P, Poynard T, (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293. doi:10.1002/hep.510240201. PubMed: 8690394.
17. Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, et al. (2007) Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 5: 636-641. doi:10.1016/j.cgh.2007.01.005. PubMed: 17428739.
18. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, et al. (2007) Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46: 395-401. doi:10.1002/hep.21724. PubMed: 17628874.
19. Liaw YF, Chu CM, (2009) Hepatitis B virus infection. Lancet 373: 582-592. doi:10.1016/S0140-6736(09)60207-5. PubMed: 19217993.
20. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, et al. (2002) Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36: 186-194. doi:10.1016/S0168-8278(02)80657-2. PubMed: 12085364.
21. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695. doi:10.1056/NEJMoa043470. PubMed: 15987917.
22. Han K, Kim D, (2008) Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2: 185-189. doi:10.1007/s12072-008-9068-z.
23. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, et al. (2008) Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 134: 1376-1384. doi:10.1053/j.gastro.2008.02.075. PubMed: 18471514.
24. Lesmana CR, Gani RA, Hasan I, Simadibrata M, Sulaiman AS, et al. (2011) Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia. J Dig Dis 12: 476-480. doi:10.1111/j.1751-2980.2011.00540.x. PubMed: 22118698.
25. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531. doi:10.1056/NEJMoa033364. PubMed: 15470215.
26. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, et al. (2009) Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 7: 227-233. doi:10.1016/j.cgh.2008.10.023. PubMed: 19121647.
27. Zoulim F, Mason WS, (2012) Reasons to consider earlier treatment of chronic HBV infections. Gut 61: 333-336. doi:10.1136/gutjnl-2012-302514d.89. PubMed: 22147510.
28. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A, (2012) Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 57: 196-202. doi:10.1016/j.jhep.2011.11.030. PubMed: 22450396.
29. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, et al. (2002) Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36: 543-546. doi:10.1016/S0168-8278(02)00004-1. PubMed: 11943427.
30. Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, et al. (2008) Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 48: 1451-1459. doi:10.1002/hep.22518. PubMed: 18924246.
31. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, et al. (2006) Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 119: 977-985. doi:10.1016/j.amjmed.2006.04.036. PubMed: 17071167.
32. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, et al. (2008) Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am J Gastroenterol 103: 3071-3081. doi:10.1111/j.1572-0241.2008.02157.x. PubMed: 19086958.
33. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, et al. (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138: 1747-1754. doi:10.1053/j.gastro.2010.01.042. PubMed: 20114048.
34. Prati D, Taioli E, Zanella A, Della TE, Butelli S, et al. (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137: 1-10. doi:10.7326/0003-4819-137-8-200210150-00027-w1. PubMed: 12093239.
35. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, et al. (2010) Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51: 1577-1583. doi:10.1002/hep.23505. PubMed: 20162730.
36. Assy N, Beniashvili Z, Djibre A, Nasser G, Grosovski M, et al. (2009) Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers. World J Gastroenterol 15: 3025-3031. doi:10.3748/wjg.15.3025. PubMed: 19554656.
37. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH, (2007) The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47: 760-767. doi:10.1016/j.jhep.2007.07.022. PubMed: 17928090.
38. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, et al. (2009) Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 49: 1859-1867. doi:10.1002/hep.22878. PubMed: 19378345.
39. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, et al. (2005) Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 100: 616-623. doi:10.1111/j.1572-0241.2005.41289.x. PubMed: 15743360.